La cadena de opciones muestra datos clave de las opciones de acciones de Puma Biotechnology a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Puma Biotechnology..

Puma Biotechnology (NASDAQ:PBYI) Bolsa, Cadena de Opciones

PUMA BIOTECHNOLOGY INC

Puma Biotechnology

Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.

Puma Biotechnology Inc

News

Guidance

PBYI

CORRECTION: Puma Biotechnology Sees Q2 Sales $50.000M-$53.000M vs $52.75M Est

CORRECTION: Puma Biotechnology Affirms FY2025 Sales Guidance of $212.00M-$222.00M vs $217.80M Est

Puma Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBYI#NASDAQ">PBYI</a>) reported quarterly earnings of $0.10 per share which beat the analyst consensus estimate of $(0.02) by 600 percent. This is a 300 percent increase over losses of $(0.05) per share from the same period last year. The company reported quarterly sales of $46.00 million which beat the analyst consensus estimate of $44.55 million by 3.25 percent. This is a 5.02 percent increase over sales of $43.80 million the same period last year.

Earnings

Earnings Beats

Puma Biotechnology Q1 Adj. EPS $0.10 Beats $(0.02) Estimate, Sales $46.00M Beat $44.55M Estimate

AAOI

ABCL

ABEV

ACIC

ACIW

ACMR

ACTG

AFRM

AKAM

AKBA

ALGM

ALIT

ALRM

ALXO

Amplify YieldShares Oil Hedged MLP Income ETF

AMLX

AMPX

AMTX

APPN

APYX

AQMS

ARGX

ARHS

ARKO

ARLO

ASPN

ASTH

Adtalem Global Education Inc. Common Stock

ATGE

ATHM

ATUS

AUTL

AVAH

AVPT

AXGN

BAER

BBDC

BIGC

BILL

BIRD

BlackSky Technology Inc. Class A Common Stock

BKSY

BLFS

BLND

CARG

CARS

CBLL

CBUS

CCEC

CCOI

CCRD

CDTX

CION

CLAR

CLFD

CLNE

CLSK

CMPS

CMRE

CODX

COIN

COLD

COLL

COMP

CRNX

CRON

CROX

CRVS

CTEV

CTKB

CTLP

CVRX

DAVE

DCGO

DCTH

DIOD

DKNG

Earnings Scheduled For May 8, 2025

Puma Biotechnology Presents Clinical Data Of Phase I Trial Of trastuzumab deruxtecan In Combination With Neratinib In Solid Tumors With HER2 Alterations At AACR 2025

WIIM

Puma Biotechnology shares are trading higher after the company reported better-than-expected Q4 financial results.

HC Wainwright &amp; Co. analyst Edward White reiterates Puma Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBYI#NASDAQ">PBYI</a>) with a Buy and maintains $7 price target.

Price Target

Reiteration

Analyst Ratings

HC Wainwright & Co. Reiterates Buy on Puma Biotechnology, Maintains $7 Price Target

Puma Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBYI#NASDAQ">PBYI</a>) sees Q1 sales of $42.500 million-$45.500 million vs $47.50 million analyst estimate.

Puma Biotechnology Sees Q1 Sales $42.500M-$45.500M vs $47.50M Est

Puma Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBYI#NASDAQ">PBYI</a>) sees FY2025 sales of $212.000 million-$222.000 million vs $207.90 million analyst estimate.

Puma Biotechnology Sees FY2025 Sales $212.000M-$222.000M vs $207.90M Est

Puma Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBYI#NASDAQ">PBYI</a>) reported quarterly earnings of $0.43 per share which beat the analyst consensus estimate of $0.10 by 330 percent. This is a 38.71 percent increase over earnings of $0.31 per share from the same period last year. The company reported quarterly sales of $59.10 million which beat the analyst consensus estimate of $52.50 million by 12.57 percent. This is a 18.14 percent decrease over sales of $72.20 million the same period last year.

Puma Biotechnology Q4 Adj EPS $0.43 Beats $0.10 Estimate, Sales $59.10M Beat $52.50M Estimate

AAON

ACEL

ACHC

ACHR

ADSK

AIRG

ALEX

ALHC

ALKT

ALTM

AMBP

AMPH

AMRC

AMWD

ARRY

AUPH

BBWI

BCSF

BECN

BWMX

CABO

CDXS

CLCO

CLOV

CMBT

CMLS

CODI

CRDF

CSTL

CUBE

CVEO

CYTK

DAIO

DELL

DUOL

ECVT

EFXT

ERIE

Embraer-Empresa Brasileira De Aeronautica

ESEA

ESTC

EVRG

EXFY

FIGS

FOXF

FTDR

FWONA

FWONK

GBTG

GDEN

GDOT

GDRX

Earnings Scheduled For February 27, 2025

Biotech

General

Puma Biotechnology's NERLYNX Added To NCCN Guidelines For HER2-Mutated Cervical Cancer; Approved As Second-Line Therapy For Recurrent Or Metastatic Disease Based On Phase II SUMMIT Trial Results

Puma Biotechnology Initiates ALISCA™-Breast1 Phase II Trial Of Alisertib In Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer

Puma Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBYI#NASDAQ">PBYI</a>) .

Puma Biotechnology expects Q424 Net Product Revenue: $46M-$48M; FY2024: $187M-$190M (Prev. $183M-$190M).

Puma Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBYI#NASDAQ">PBYI</a>) reported quarterly earnings of $0.45 per share which beat the analyst consensus estimate of $0.35 by 28.57 percent. The company reported quarterly sales of $80.500 million which beat the analyst consensus estimate of $70.650 million by 13.94 percent. This is a 43.49 percent increase over sales of $56.100 million the same period last year.

Puma Biotechnology Q3 2024 Adj. EPS $0.45 Beats $0.35 Estimate, Sales $80.500M Beat $70.650M Estimate

<h3>Gainers</h3>
<ul>
<li>Inspire Veterinary (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVP#NASDAQ">IVP</a>) stock rose 10.8% to $0.27 during Tuesday's after-market session. The company's market cap stands at $1.9 million. </li>
<li>CASI Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CASI#NASDAQ">CASI</a>) shares moved upwards by 9.44% to $6.14. The market value of their outstanding shares is at $94.9 million. </li>
<li>Shuttle Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHPH#NASDAQ">SHPH</a>) stock increased by 7.42% to $1.3. The market value of their outstanding shares is at $3.8 million. </li>
<li>Immunome (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMNM#NASDAQ">IMNM</a>) stock increased by 7.32% to $14.51. The market value of their outstanding shares is at $871.3 million. </li>
<li>Carmell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTCX#NASDAQ">CTCX</a>) shares increased by 7.18% to $0.43. The market value of their outstanding shares is at $9.0 million. </li>
<li>Gritstone Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRTS#NASDAQ">GRTS</a>) shares increased by 6.86% to $0.23. The market value of their outstanding shares is at $27.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Nuwellis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUWE#NASDAQ">NUWE</a>) stock declined by 5.4% to $1.4 during Tuesday's after-market session. The market value of their outstanding shares is at $2.6 million. </li>
<li>Puma Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBYI#NASDAQ">PBYI</a>) stock declined by 5.0% to $2.47. The company's market cap stands at $119.1 million. </li>
<li>Agape ATP (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATPC#NASDAQ">ATPC</a>) shares fell 4.98% to $1.79. The company's market cap stands at $6.8 million. </li>
<li>Aerovate Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVTE#NASDAQ">AVTE</a>) shares decreased by 4.84% to $1.97. The company's market cap stands at $56.8 million. </li>
<li>Alpha Teknova (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TKNO#NASDAQ">TKNO</a>) shares decreased by 4.4% to $4.35. The market value of their outstanding shares is at $231.8 million. </li>
<li>Know Labs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KNW#AMEX">KNW</a>) stock declined by 4.2% to $0.27. The company's market cap stands at $29.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ATPC

AVTE

CASI

CTCX

GRTS

IMNM

NUWE

SHPH

TKNO

12 Health Care Stocks Moving In Tuesday's After-Market Session

Press Releases

Puma Biotechnology Reports Fourth Quarter and Full Year 2024 Financial Results

Puma Biotechnology to Present at Barclays Annual Global Healthcare Conference

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology to Present Clinical Data on Neratinib at the AACR Annual Meeting 2025

Puma Biotechnology to Host Conference Call to Discuss First Quarter 2025 Financial Results

Puma Biotechnology Presents Clinical Data on Neratinib at the AACR Annual Meeting 2025

Er-Kim Announces Exclusive Distribution Agreement with Puma Biotechnology to Commercialize NERLYNX® (neratinib) for Breast Cancer Patients

Comments

Puma Biotechnology

Puma Biotechnology (PBYI) Opciones

Puma Biotechnology (NASDAQ:PBYI) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL